Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction

Inclusion Criteria: * Men of ages between 30-75 years with indication for nerve-sparing prostatectomy surgery; * Cancer stage T1c and T2a; * Grade Groups 1 and 2 as well as low volume Grade Group 3 (Gleason score 4 + 3 = 7), as determined by biopsy (2 cores or less GG3) or single index MRI lesion of GG3 disease; * IIEF-15 erectile function domain score equal to or greater than 26; * Men interested in minimizing the effect of radical prostatectomy on erectile function; * Ability to read and understand patient information materials and willingness to sign a written informed consent. Exclusion Criteria: * Men with neurological disease, including a history of spinal cord injury or trauma; * IIEF-15 erectile function domain score less than 26; * Failure to demonstrate adequate nocturne erectile function prioi prostatectomy (nocturnal RigiScan measure); * Men with PSA \> 20 ng/mL; * History of ED, priapism and Peyronie disease; * History of previous pelvic surgery, trauma or irradiation therapy; * Currently have an active implantable device. * Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions; * Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation; * Inability to understand and demonstrate device use instructions; * Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications; * Patient unwillingness to e…